The Significance of Vasoactive Intestinal Peptide in Immunomodulation

  title={The Significance of Vasoactive Intestinal Peptide in Immunomodulation},
  author={Mario Delgado and David Pozo and Doina Ganea},
  journal={Pharmacological Reviews},
  pages={249 - 290}
First identified by Said and Mutt some 30 years ago, the vasoactive intestinal peptide (VIP) was originally isolated as a vasodilator peptide. Subsequently, its biochemistry was elucidated, and within the 1st decade, their signature features as a neuropeptide became consolidated. It did not take long for these insights to permeate the field of immunology, out of which surprising new attributes for VIP were found in the last years. VIP is rapidly transforming into something more than a mere… 

Figures and Tables from this paper

Vasoactive intestinal peptide, periodontal disease, and the innate immune response: an interview with Dr. John J. Taylor

The work of Rosa Gomariz and colleagues from Universidad Complutense in Madrid, Spain has shown that administration of VIP to mice with trinitrobenzene sulfonic acid (TNBS)-induced colitis results in diminished disease in correlation with diminished expression of TLRs 2 and 4 in macrophages, dendritic cells, and lymphocytes, the first bit of data that suggested that there might be regulatory mechanisms at an earlier stage of the inflammatory response.

The neuropeptide vasoactive intestinal peptide: direct effects on immune cells and involvement in inflammatory and autoimmune diseases

The current information on VIP production and VIP‐receptor‐mediated effects in the immune system, the role of endogenous and exogenous VIP in inflammatory and autoimmune disorders and the present and future VIP therapeutic approaches are reviewed.

Emerging roles of vasoactive intestinal peptide: a new approach for autoimmune therapy

The latest research findings indicate that VIP participates in maintaining immune tolerance in two distinct ways: by regulating the balance between pro-inflammatory and anti-inflammatory factors, and by inducing the emergence of regulatory T cells with suppressive activity against autoreactive T cell effectors.

Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system

The impact of VIP on gastrointestinal function and diseases based on recent findings is discussed, also providing insight into its possible therapeutic application to diabetes, autoimmune diseases and cancer.

VIP and PACAP as Regulators of Immunity: New Perspectives from A Receptor Point of View

This review focuses on the relevance of the VPAC2 receptor on VIP and PACAP modulation of immune responses, and discusses its potential as a target for the treatment of Th1-driven inflammatory disorders.

Themed Section : Secretin Family ( Class B ) G Protein-Coupled Receptors – from Molecular to Clinical Perspectives

Recent advances in the structural characterization of VPAC receptor and more generally of class B GPCRs will lead to the design of new molecules, which could have considerable interest for the treatment of inflammatory and neuro-degenerative diseases.

Recent advances in vasoactive intestinal peptide physiology

The impact of VIP on gastrointestinal function and diseases based on recent findings is discussed, also providing insight into its possible therapeutic application to diabetes, autoimmune diseases and cancer.

Role of vasoactive intestinal peptide in osteoarthritis

Vasoactive intestinal peptide (VIP) plays important roles in many biological functions, such as, stimulation of contractility in the heart, vasodilation, promoting neuroendocrine-immune



Immunology of VIP: a review and therapeutical perspectives.

Although VIP has been classically considered as an immunodepressant agent, several evidences suggest that a better way to see this peptide is as a modulator of the homeostasis of the immune system.

Vasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune diseases

VIP has been proposed as a promising candidate alternative treatment for acute and chronic inflammatory and autoimmune diseases such as septic shock, arthritis, multiple sclerosis, Crohn disease, or autoimmune diabetes.

The significance of vasoactive intestinal polypeptide (VIP) in immunomodulation.


The opening speech of Dr Tunçel and a set of selective abstracts of the Antalya INPS Meeting 2001 are presented, cultivating much a new thinking about the therapeutic potentials of various neuropeptides and neurotrophins.

The effects of vasoactive intestinal peptide on human natural killer cell function.

Data suggest a functional role for VIP in modulating immune responses during neuroendocrine interactions with the immune system, and the integrity of the 14-28 C-terminal amino acid sequence was essential for its activity in cytotoxicity.

Cutting Edge: Is Vasoactive Intestinal Peptide a Type 2 Cytokine?

Investigation of whether T cell subsets differentially express VIP finds that, upon specific Ag stimulation, Th2 and T2 cells, but not Th1 and T1 cells derived from TCR transgenic (Tg) mice, express VIP mRNA and protein, and secrete VIP.

Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: players in innate and adaptive immunity.

The immunomodulatory role of two peptides, the vasoactive intestinal peptide (VIP) and the pituitary adenylate cyclase-activating polypeptide (PACAP), which are present and released from both innervation and immune cells, particularly Th2 cells, are focused on.

Vasoactive intestinal peptide inhibits IL-8 production in human monocytes.